By / December 27, 2019

German cannabis startups continue to earn millions

Canopy Growth took over one of the largest German cannabis startups to date.

The Canadian cannabis company bought the cannabis division of Bionorica, a natural remedy manufacturer based in the Upper Palatinate, for $250 million (€226 million).

Cannabis has been of huge interest to investors on the stock exchange for several years. More countries continue to legalize cannabis for medical use. Tobacco companies and beverage manufacturers have also entered the emerging industries for a great deal of money.

To keep up-to-date with the market, check out the app. The application is exclusively dedicated to hemp and cannabis and focuses on the latest cannabis news, economic trends, medical information, investing news and blockchain.

German cannabis startups are of great interest to investors

After the cannabis legalization boom of 2018, not many new markets have been added. In the place where cannabis is only available for medical purposes, sales have been limited by strict sales regulations.

The areas under cultivation have grown much faster than the demand, and thus, the quantities harvested.

According to the local health authorities, the hemp stocks stored in Canada have almost quadrupled within a year to around 400 tonnes. This corresponds to the quantity consumed in Canada in two and a half years.

Not all expectations have been fulfilled for Germany’s cannabis startups either. The Frankfurt cannabis trader Farmako, who started with great potential, had estimated its market value at $110 million (€100 million) but was then taken over for only a fraction of that.

Professional investors still see opportunities in Germany

business people thinking about investing in German cannabis startups
Investors see a great opportunity in German cannabis startups due to the popularity of the plant in the region. (Source)

Finn Hänsel is only in his mid-thirties but is already a veteran among the cannabis decriminalization movement in Germany. He still sees some opportunities for investment in Germany.

A year ago, Hänsel, together with his partner, founded the company Sanity Group. Their business model is the importation of medical cannabis to Germany as well as the distribution of hemp-containing, non-prescription cosmetic and lifestyle products such as bath additives.

“We are also working on new dosage forms for cannabis patients,” said Hänsel.

He does not yet want to reveal exactly what this is all about. However, it is easy to imagine that there could also be inhalation aids (inhalers) that would make consuming cannabis easier.

Finding new investors for German cannabis startups

A group making a deal with  German cannabis startups
Although some investors still doubt the future of the market, many maintain the trust of their investments. (Source)

Hänsel is currently looking for new investors for his company.

“The new realism of the cannabis market is not bothering him. Many competitors have invested a disproportionate amount of money in the construction of large greenhouses in Canada and Denmark, where the climate conditions for growing cannabis are not particularly favorable,” he claims.

He explains that in Canada, the production costs for one gram are around $3.30 (€3) while in Israel, it’s only $0.20.

“Our production sites in the Mediterranean area would prevail in the long run and it is precisely from there that Sanity would mainly source its products,” he continued. “$10 million in additional capital has already been promised and this amount will be added in the coming weeks.”

An IPO, Hänsel admits, is currently not conceivable. The mood among investors is too volatile for that.


(Featured image by noelsch via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Frankfurter Allgemeine, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.